Cell Therapies under Clinical Trials and Polarized Cell Therapies in Pre-Clinical Studies to Treat Ischemic Stroke and Neurological Diseases: A Literature Review.
Cell Therapies under Clinical Trials and Polarized Cell Therapies in Pre-Clinical Studies to Treat Ischemic Stroke and Neurological Diseases: A Literature Review.
复制标题
DOI：
10.3390/ijms21176194
复制
发表时间：
2020-08-27
影响因子：
5.6
通讯作者：
Kanazawa M
中科院分区：
文献类型：
--
作者：
Hatakeyama M;Ninomiya I;Otsu Y;Omae K;Kimura Y;Onodera O;Fukushima M;Shimohata T;Kanazawa M
中风仍然是导致严重残疾的主要原因，因为大脑的再生能力有限。在过去的二十年里，中风的治疗方法发生了戏剧性的变化。然而，有一半的患者在治疗后无法实现功能独立。目前，基于细胞的治疗正在被研究以改善功能结果。该综述旨在描述正在进行临床试验的常规细胞疗法，并概述目前处于临床前研究的基于保护性细胞表型的极化细胞疗法的新概念，以促进缺血性卒中患者再灌注治疗后的功能恢复。特别是，非神经元干细胞，如骨髓来源的间充质干细胞/基质细胞和单个核细胞，不存在肿瘤形成的风险，并且因为它们不会引起排斥和过敏而是安全的；它们也不会造成伦理问题。因此，最近的研究集中在它们作为细胞治疗的细胞来源上。一些临床试验表明，骨髓来源的细胞在这方面具有有益的治疗作用，而另一些临床试验则没有这种作用。因此，必须进行更多的临床试验才能得出结论。极化的小胶质细胞或外周血单核细胞可能为卒中后提供有前景的治疗策略，因为它们具有多效性。在创伤和神经退行性疾病中，在临床前研究中，星形胶质细胞、中性粒细胞和T细胞被极化到保护性表型。因此，它们可能是有用的治疗靶点。极化细胞疗法在中风和神经系统疾病的治疗中正受到越来越多的关注。
Stroke remains a major cause of serious disability because the brain has a limited capacity to regenerate. In the last two decades, therapies for stroke have dramatically changed. However, half of the patients cannot achieve functional independence after treatment. Presently, cell-based therapies are being investigated to improve functional outcomes. This review aims to describe conventional cell therapies under clinical trial and outline the novel concept of polarized cell therapies based on protective cell phenotypes, which are currently in pre-clinical studies, to facilitate functional recovery after post-reperfusion treatment in patients with ischemic stroke. In particular, non-neuronal stem cells, such as bone marrow-derived mesenchymal stem/stromal cells and mononuclear cells, confer no risk of tumorigenesis and are safe because they do not induce rejection and allergy; they also pose no ethical issues. Therefore, recent studies have focused on them as a cell source for cell therapies. Some clinical trials have shown beneficial therapeutic effects of bone marrow-derived cells in this regard, whereas others have shown no such effects. Therefore, more clinical trials must be performed to reach a conclusion. Polarized microglia or peripheral blood mononuclear cells might provide promising therapeutic strategies after stroke because they have pleiotropic effects. In traumatic injuries and neurodegenerative diseases, astrocytes, neutrophils, and T cells were polarized to the protective phenotype in pre-clinical studies. As such, they might be useful therapeutic targets. Polarized cell therapies are gaining attention in the treatment of stroke and neurological diseases.
登录
查看更多内容
影响因子：
11.1
作者：
Fujioka T;Kaneko N;Ajioka I;Nakaguchi K;Omata T;Ohba H;Fässler R;García-Verdugo JM;Sekiguchi K;Matsukawa N;Sawamoto K
通讯作者：
Sawamoto K
影响因子：
5.6
作者：
Geiseler SJ;Morland C
通讯作者：
Morland C
影响因子：
158.5
作者：
Berkhemer, O. A.;Fransen, P. S. S.;Dippel, D. W. J.
通讯作者：
Dippel, D. W. J.
影响因子：
3.4
作者：
Ghali AA;Yousef MK;Ragab OA;ElZamarany EA
通讯作者：
ElZamarany EA
DOI：
10.1093/brain/awr094
发表时间：
2011-06
期刊：
Brain : a journal of neurology
影响因子：
--
作者：
Andres RH;Horie N;Slikker W;Keren-Gill H;Zhan K;Sun G;Manley NC;Pereira MP;Sheikh LA;McMillan EL;Schaar BT;Svendsen CN;Bliss TM;Steinberg GK
通讯作者：
Steinberg GK